Skip to main content
. 2010 May;24(5):1479–1488. doi: 10.1096/fj.09-144733

Figure 3.

Figure 3.

Inhibition of type I IFN antiviral activity by VACV IFNα/βBP and its VARV and MPXV orthologues. Supernatants containing the indicated recombinant proteins were preincubated with 50 U of each type I IFN and subsequently added to HeLa cell monolayers. After a 16 h incubation, cells were infected with VSV, and cell viability was determined after 48 h. Controls of nontreated, uninfected (−VSV), and infected (+VSV) cells are at left, separated by a dashed line. Results are means ± sd of triplicate samples from one representative experiment.